ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Influenza Subunit Vaccine Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-34O16627
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Influenza Subunit Vaccine Market Research Report 2024
BUY CHAPTERS

Global Influenza Subunit Vaccine Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-34O16627
Report
November 2025
Pages:123
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Sanofi
Seqirus
Ab&B BIO-TECH
Zhongyianke Biology
Ab&B BIO-TECH

Influenza Subunit Vaccine Market

The global Influenza Subunit Vaccine market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Influenza subunit vaccine is a type of vaccine used to prevent influenza. It contains specific protein subunits of the influenza virus, usually the influenza virus hemagglutinin and neuraminidase. These subunits stimulate the body's immune system to produce antibodies that provide protection when infected with the influenza virus.
From a downstream perspective, Aldult accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Influenza Subunit Vaccine leading manufacturers including Ab&B BIO-TECH, Sanofi, Seqirus, Inc, Zhongyianke Biology, etc., dominate supply; the top five capture approximately % of global revenue, with Ab&B BIO-TECH leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Influenza Subunit Vaccine market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Influenza Subunit Vaccine Market Report

Report Metric Details
Report Name Influenza Subunit Vaccine Market
Segment by Type
  • Trivalent Vaccines
  • Tetravalent Vaccine
Segment by Application
  • Aldult
  • Child
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Ab&B BIO-TECH, Sanofi, Seqirus, Inc, Zhongyianke Biology
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Influenza Subunit Vaccine study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
  • Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 15: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Influenza Subunit Vaccine Market report?

Ans: The main players in the Influenza Subunit Vaccine Market are Ab&B BIO-TECH, Sanofi, Seqirus, Inc, Zhongyianke Biology

What are the Application segmentation covered in the Influenza Subunit Vaccine Market report?

Ans: The Applications covered in the Influenza Subunit Vaccine Market report are Aldult, Child

What are the Type segmentation covered in the Influenza Subunit Vaccine Market report?

Ans: The Types covered in the Influenza Subunit Vaccine Market report are Trivalent Vaccines, Tetravalent Vaccine

1 Study Coverage
1.1 Introduction to Influenza Subunit Vaccine: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Influenza Subunit Vaccine Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Trivalent Vaccines
1.2.3 Tetravalent Vaccine
1.3 Market Segmentation by Application
1.3.1 Global Influenza Subunit Vaccine Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Aldult
1.3.3 Child
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Influenza Subunit Vaccine Revenue Estimates and Forecasts 2020-2031
2.2 Global Influenza Subunit Vaccine Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Influenza Subunit Vaccine Sales Estimates and Forecasts 2020-2031
2.4 Global Influenza Subunit Vaccine Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Influenza Subunit Vaccine Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Influenza Subunit Vaccine Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Trivalent Vaccines Market Size by Manufacturers
3.5.2 Tetravalent Vaccine Market Size by Manufacturers
3.6 Global Influenza Subunit Vaccine Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Influenza Subunit Vaccine Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Influenza Subunit Vaccine Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Influenza Subunit Vaccine Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Influenza Subunit Vaccine Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Influenza Subunit Vaccine Sales and Revenue by Type (2020-2031)
6.4 North America Influenza Subunit Vaccine Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Influenza Subunit Vaccine Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Influenza Subunit Vaccine Sales and Revenue by Type (2020-2031)
7.4 Europe Influenza Subunit Vaccine Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Influenza Subunit Vaccine Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Influenza Subunit Vaccine Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Influenza Subunit Vaccine Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Influenza Subunit Vaccine Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Influenza Subunit Vaccine Sales and Revenue by Type (2020-2031)
9.4 Central and South America Influenza Subunit Vaccine Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Influenza Subunit Vaccine Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Influenza Subunit Vaccine Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Influenza Subunit Vaccine Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Influenza Subunit Vaccine Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Ab&B BIO-TECH
11.1.1 Ab&B BIO-TECH Corporation Information
11.1.2 Ab&B BIO-TECH Business Overview
11.1.3 Ab&B BIO-TECH Influenza Subunit Vaccine Product Models, Descriptions and Specifications
11.1.4 Ab&B BIO-TECH Influenza Subunit Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Ab&B BIO-TECH Influenza Subunit Vaccine Sales by Product in 2024
11.1.6 Ab&B BIO-TECH Influenza Subunit Vaccine Sales by Application in 2024
11.1.7 Ab&B BIO-TECH Influenza Subunit Vaccine Sales by Geographic Area in 2024
11.1.8 Ab&B BIO-TECH Influenza Subunit Vaccine SWOT Analysis
11.1.9 Ab&B BIO-TECH Recent Developments
11.2 Sanofi
11.2.1 Sanofi Corporation Information
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Influenza Subunit Vaccine Product Models, Descriptions and Specifications
11.2.4 Sanofi Influenza Subunit Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Sanofi Influenza Subunit Vaccine Sales by Product in 2024
11.2.6 Sanofi Influenza Subunit Vaccine Sales by Application in 2024
11.2.7 Sanofi Influenza Subunit Vaccine Sales by Geographic Area in 2024
11.2.8 Sanofi Influenza Subunit Vaccine SWOT Analysis
11.2.9 Sanofi Recent Developments
11.3 Seqirus, Inc
11.3.1 Seqirus, Inc Corporation Information
11.3.2 Seqirus, Inc Business Overview
11.3.3 Seqirus, Inc Influenza Subunit Vaccine Product Models, Descriptions and Specifications
11.3.4 Seqirus, Inc Influenza Subunit Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Seqirus, Inc Influenza Subunit Vaccine Sales by Product in 2024
11.3.6 Seqirus, Inc Influenza Subunit Vaccine Sales by Application in 2024
11.3.7 Seqirus, Inc Influenza Subunit Vaccine Sales by Geographic Area in 2024
11.3.8 Seqirus, Inc Influenza Subunit Vaccine SWOT Analysis
11.3.9 Seqirus, Inc Recent Developments
11.4 Zhongyianke Biology
11.4.1 Zhongyianke Biology Corporation Information
11.4.2 Zhongyianke Biology Business Overview
11.4.3 Zhongyianke Biology Influenza Subunit Vaccine Product Models, Descriptions and Specifications
11.4.4 Zhongyianke Biology Influenza Subunit Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Zhongyianke Biology Influenza Subunit Vaccine Sales by Product in 2024
11.4.6 Zhongyianke Biology Influenza Subunit Vaccine Sales by Application in 2024
11.4.7 Zhongyianke Biology Influenza Subunit Vaccine Sales by Geographic Area in 2024
11.4.8 Zhongyianke Biology Influenza Subunit Vaccine SWOT Analysis
11.4.9 Zhongyianke Biology Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Influenza Subunit Vaccine Industry Chain
12.2 Influenza Subunit Vaccine Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Influenza Subunit Vaccine Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Influenza Subunit Vaccine Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Influenza Subunit Vaccine Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Influenza Subunit Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Sanofi
Seqirus
Ab&B BIO-TECH
Zhongyianke Biology
Ab&B BIO-TECH
List of Tables
 Table 1. Global Influenza Subunit Vaccine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Influenza Subunit Vaccine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Influenza Subunit Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Influenza Subunit Vaccine Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Influenza Subunit Vaccine Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Global Influenza Subunit Vaccine Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
 Table 7. Global Influenza Subunit Vaccine Sales by Region (2020-2025) & (K Units)
 Table 8. Global Influenza Subunit Vaccine Sales by Region (2026-2031) & (K Units)
 Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 10. Global Influenza Subunit Vaccine Sales by Manufacturers (2020-2025) & (K Units)
 Table 11. Global Influenza Subunit Vaccine Sales Share by Manufacturers (2020-2025)
 Table 12. Global Influenza Subunit Vaccine Revenue by Manufacturers (2020-2025) & (US$ Million)
 Table 13. Global Influenza Subunit Vaccine Revenue Market Share by Manufacturers (2020-2025)
 Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 15. Global Influenza Subunit Vaccine by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza Subunit Vaccine as of 2024)
 Table 16. Global Influenza Subunit Vaccine Average Gross Margin (%) by Manufacturer (2020 VS 2024)
 Table 17. Global Influenza Subunit Vaccine Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
 Table 18. Key Manufacturers Influenza Subunit Vaccine Manufacturing Base and Headquarters
 Table 19. Global Influenza Subunit Vaccine Market Concentration Ratio (CR5 and HHI)
 Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 22. Global Influenza Subunit Vaccine Sales by Type (2020-2025) & (K Units)
 Table 23. Global Influenza Subunit Vaccine Sales by Type (2026-2031) & (K Units)
 Table 24. Global Influenza Subunit Vaccine Revenue by Type (2020-2025) & (US$ Million)
 Table 25. Global Influenza Subunit Vaccine Revenue by Type (2026-2031) & (US$ Million)
 Table 26. Global Influenza Subunit Vaccine ASP by Type (2020-2031) & (US$/Unit)
 Table 27. Technical Specifications by Key Product Type
 Table 28. Global Influenza Subunit Vaccine Sales by Application (2020-2025) & (K Units)
 Table 29. Global Influenza Subunit Vaccine Sales by Application (2026-2031) & (K Units)
 Table 30. Influenza Subunit Vaccine High-Growth Sectors Demand CAGR (2024-2031)
 Table 31. Global Influenza Subunit Vaccine Revenue by Application (2020-2025) & (US$ Million)
 Table 32. Global Influenza Subunit Vaccine Revenue by Application (2026-2031) & (US$ Million)
 Table 33. Global Influenza Subunit Vaccine ASP by Application (2020-2031) & (US$/Unit)
 Table 34. Top Customers by Region
 Table 35. Top Customers by Application
 Table 36. North America Influenza Subunit Vaccine Growth Accelerators and Market Barriers
 Table 37. North America Influenza Subunit Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 38. North America Influenza Subunit Vaccine Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 39. Europe Influenza Subunit Vaccine Growth Accelerators and Market Barriers
 Table 40. Europe Influenza Subunit Vaccine Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Europe Influenza Subunit Vaccine Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 42. Asia-Pacific Influenza Subunit Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Asia-Pacific Influenza Subunit Vaccine Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 44. Asia-Pacific Influenza Subunit Vaccine Growth Accelerators and Market Barriers
 Table 45. Southeast Asia Influenza Subunit Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Central and South America Influenza Subunit Vaccine Investment Opportunities and Key Challenges
 Table 47. Central and South America Influenza Subunit Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 48. Middle East and Africa Influenza Subunit Vaccine Investment Opportunities and Key Challenges
 Table 49. Middle East and Africa Influenza Subunit Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 50. Ab&B BIO-TECH Corporation Information
 Table 51. Ab&B BIO-TECH Description and Major Businesses
 Table 52. Ab&B BIO-TECH Product Models, Descriptions and Specifications
 Table 53. Ab&B BIO-TECH Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 54. Ab&B BIO-TECH Sales Value Proportion by Product in 2024
 Table 55. Ab&B BIO-TECH Sales Value Proportion by Application in 2024
 Table 56. Ab&B BIO-TECH Sales Value Proportion by Geographic Area in 2024
 Table 57. Ab&B BIO-TECH Influenza Subunit Vaccine SWOT Analysis
 Table 58. Ab&B BIO-TECH Recent Developments
 Table 59. Sanofi Corporation Information
 Table 60. Sanofi Description and Major Businesses
 Table 61. Sanofi Product Models, Descriptions and Specifications
 Table 62. Sanofi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 63. Sanofi Sales Value Proportion by Product in 2024
 Table 64. Sanofi Sales Value Proportion by Application in 2024
 Table 65. Sanofi Sales Value Proportion by Geographic Area in 2024
 Table 66. Sanofi Influenza Subunit Vaccine SWOT Analysis
 Table 67. Sanofi Recent Developments
 Table 68. Seqirus, Inc Corporation Information
 Table 69. Seqirus, Inc Description and Major Businesses
 Table 70. Seqirus, Inc Product Models, Descriptions and Specifications
 Table 71. Seqirus, Inc Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 72. Seqirus, Inc Sales Value Proportion by Product in 2024
 Table 73. Seqirus, Inc Sales Value Proportion by Application in 2024
 Table 74. Seqirus, Inc Sales Value Proportion by Geographic Area in 2024
 Table 75. Seqirus, Inc Influenza Subunit Vaccine SWOT Analysis
 Table 76. Seqirus, Inc Recent Developments
 Table 77. Zhongyianke Biology Corporation Information
 Table 78. Zhongyianke Biology Description and Major Businesses
 Table 79. Zhongyianke Biology Product Models, Descriptions and Specifications
 Table 80. Zhongyianke Biology Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 81. Zhongyianke Biology Sales Value Proportion by Product in 2024
 Table 82. Zhongyianke Biology Sales Value Proportion by Application in 2024
 Table 83. Zhongyianke Biology Sales Value Proportion by Geographic Area in 2024
 Table 84. Zhongyianke Biology Influenza Subunit Vaccine SWOT Analysis
 Table 85. Zhongyianke Biology Recent Developments
 Table 86. Key Raw Materials Distribution
 Table 87. Raw Materials Key Suppliers
 Table 88. Critical Raw Material Supplier Concentration (2024) & Risk Index
 Table 89. Milestones in Production Technology Evolution
 Table 90. Distributors List
 Table 91. Market Trends and Market Evolution
 Table 92. Market Drivers and Opportunities
 Table 93. Market Challenges, Risks, and Restraints
 Table 94. Research Programs/Design for This Report
 Table 95. Key Data Information from Secondary Sources
 Table 96. Key Data Information from Primary Sources


List of Figures
 Figure 1. Influenza Subunit Vaccine Product Picture
 Figure 2. Global Influenza Subunit Vaccine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Trivalent Vaccines Product Picture
 Figure 4. Tetravalent Vaccine Product Picture
 Figure 5. Global Influenza Subunit Vaccine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 6. Aldult
 Figure 7. Child
 Figure 8. Influenza Subunit Vaccine Report Years Considered
 Figure 9. Global Influenza Subunit Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 10. Global Influenza Subunit Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 11. Global Influenza Subunit Vaccine Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 12. Global Influenza Subunit Vaccine Revenue Market Share by Region (2020-2031)
 Figure 13. Global Influenza Subunit Vaccine Sales (2020-2031) & (K Units)
 Figure 14. Global Influenza Subunit Vaccine Sales (CAGR) by Region (2020-2031) (K Units)
 Figure 15. Global Influenza Subunit Vaccine Sales Market Share by Region (2020-2031)
 Figure 16. Top 5 and Top 10 Manufacturers Influenza Subunit Vaccine Sales Volume Market Share in 2024
 Figure 17. Global Influenza Subunit Vaccine Revenue Market Share Ranking (2024)
 Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 19. Trivalent Vaccines Revenue Market Share by Manufacturer in 2024
 Figure 20. Tetravalent Vaccine Revenue Market Share by Manufacturer in 2024
 Figure 21. Global Influenza Subunit Vaccine Sales Market Share by Type (2020-2031)
 Figure 22. Global Influenza Subunit Vaccine Revenue Market Share by Type (2020-2031)
 Figure 23. Global Influenza Subunit Vaccine Sales Market Share by Application (2020-2031)
 Figure 24. Global Influenza Subunit Vaccine Revenue Market Share by Application (2020-2031)
 Figure 25. North America Influenza Subunit Vaccine Sales YoY (2020-2031) & (K Units)
 Figure 26. North America Influenza Subunit Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 27. North America Top 5 Manufacturers Influenza Subunit Vaccine Sales Revenue (US$ Million) in 2024
 Figure 28. North America Influenza Subunit Vaccine Sales Volume (K Units) by Type (2020- 2031)
 Figure 29. North America Influenza Subunit Vaccine Sales Revenue (US$ Million) by Type (2020 - 2031)
 Figure 30. North America Influenza Subunit Vaccine Sales Volume (K Units) by Application (2020-2031)
 Figure 31. North America Influenza Subunit Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 32. US Influenza Subunit Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 33. Canada Influenza Subunit Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 34. Mexico Influenza Subunit Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 35. Europe Influenza Subunit Vaccine Sales YoY (2020-2031) & (K Units)
 Figure 36. Europe Influenza Subunit Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 37. Europe Top 5 Manufacturers Influenza Subunit Vaccine Sales Revenue (US$ Million) in 2024
 Figure 38. Europe Influenza Subunit Vaccine Sales Volume (K Units) by Type (2020-2031)
 Figure 39. Europe Influenza Subunit Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 40. Europe Influenza Subunit Vaccine Sales Volume (K Units) by Application (2020-2031)
 Figure 41. Europe Influenza Subunit Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 42. Germany Influenza Subunit Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 43. France Influenza Subunit Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 44. U.K. Influenza Subunit Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 45. Italy Influenza Subunit Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 46. Russia Influenza Subunit Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 47. Asia-Pacific Influenza Subunit Vaccine Sales YoY (2020-2031) & (K Units)
 Figure 48. Asia-Pacific Influenza Subunit Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 49. Asia-Pacific Top 8 Manufacturers Influenza Subunit Vaccine Sales Revenue (US$ Million) in 2024
 Figure 50. Asia-Pacific Influenza Subunit Vaccine Sales Volume (K Units) by Type (2020- 2031)
 Figure 51. Asia-Pacific Influenza Subunit Vaccine Sales Revenue (US$ Million) by Type (2020- 2031)
 Figure 52. Asia-Pacific Influenza Subunit Vaccine Sales Volume (K Units) by Application (2020-2031)
 Figure 53. Asia-Pacific Influenza Subunit Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 54. Indonesia Influenza Subunit Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 55. Japan Influenza Subunit Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 56. South Korea Influenza Subunit Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 57. China Taiwan Influenza Subunit Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 58. India Influenza Subunit Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 59. Central and South America Influenza Subunit Vaccine Sales YoY (2020-2031) & (K Units)
 Figure 60. Central and South America Influenza Subunit Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 61. Central and South America Top 5 Manufacturers Influenza Subunit Vaccine Sales Revenue (US$ Million) in 2024
 Figure 62. Central and South America Influenza Subunit Vaccine Sales Volume (K Units) by Type (2021-2031)
 Figure 63. Central and South America Influenza Subunit Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 64. Central and South America Influenza Subunit Vaccine Sales Volume (K Units) by Application (2020-2031)
 Figure 65. Central and South America Influenza Subunit Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 66. Brazil Influenza Subunit Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 67. Argentina Influenza Subunit Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 68. Middle East, and Africa Influenza Subunit Vaccine Sales YoY (2020-2031) & (K Units)
 Figure 69. Middle East and Africa Influenza Subunit Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 70. Middle East and Africa Top 5 Manufacturers Influenza Subunit Vaccine Sales Revenue (US$ Million) in 2024
 Figure 71. Middle East and Africa Influenza Subunit Vaccine Sales Volume (K Units) by Type (2021-2031)
 Figure 72. South America Influenza Subunit Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 73. Middle East and Africa Influenza Subunit Vaccine Sales Volume (K Units) by Application (2020-2031)
 Figure 74. Middle East and Africa Influenza Subunit Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 75. GCC Countries Influenza Subunit Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 76. Turkey Influenza Subunit Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 77. Egypt Influenza Subunit Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 78. South Africa Influenza Subunit Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 79. Influenza Subunit Vaccine Industry Chain Mapping
 Figure 80. Regional Influenza Subunit Vaccine Manufacturing Base Distribution (%)
 Figure 81. Global Influenza Subunit Vaccine Production Market Share by Region (2020-2031)
 Figure 82. Influenza Subunit Vaccine Production Process
 Figure 83. Regional Influenza Subunit Vaccine Production Cost Structure
 Figure 84. Channels of Distribution (Direct Vs Distribution)
 Figure 85. Bottom-up and Top-down Approaches for This Report
 Figure 86. Data Triangulation
 Figure 87. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

Global Injection Influenza Vaccine Market Research Report 2025
Global Adjuvanted Influenza Vaccine Market Research Report 2024
Global Inactivated Poultry Vaccine Market Research Report 2025
Global Flu Vaccination Market Research Report 2025
Global Flu Vaccine Market Insights Forecast to 2030
Global Human Injection Flu Vaccine Market Research Report 2025
Global Injection Flu Shot Market Research Report 2025
Global Flu RNA Vaccines Market Research Report 2025
Global Recombinant Influenza Vaccine Market Research Report 2024
Children Influenza Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Influenza Vaccine Split Virion Inactivated Quadrivalent Market Research Report 2024
Global Flu Prevention Market Research Report 2024
Global Egg free Flu Vaccine Market Research Report 2024
Global Viral Vector Vaccine for Humans Market Research Report 2024
Global Trivalent Split Influenza Vaccine Market Research Report 2025
Global Avian Influenza Vaccines Sales Market Report Competitive Analysis and Regional Opportunities 2025 2031
Global Travelers Vaccines Market Research Report 2025
Influenza Virus Vaccine H1N1 Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Bacterial Vaccines for Humans Market Research Report 2024
Global Poultry Vaccines Market Research Report 2025
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions